Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Absci Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VANCOUVER, WASH. AND NEW YORK, JULY 14, 2026 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER 2026 AFTER MARKET CLOSE ON TUESDAY, AUGUST 11, 2026.

ABSCI TO REPORT BUSINESS UPDATES AND SECOND QUARTER 2026 FINANCIAL AND OPERATING RESULTS ON AUGUST 11, 2026

ELI LILLY & COMPANY, ADAGE, BVF PARTNERS, COLUMBIA THREADNEEDLE, INVUS, REDMILE, AND LARGE INVESTMENT MANAGEMENT FIRM INVEST $100 MILLION IN ABSCI

ABSCI ANNOUNCES PRICING OF $100 MILLION UNDERWRITTEN OFFERING WITH LEADING STRATEGIC AND FINANCIAL INVESTORS

STUDY MEDICATION APPEARS WELL TOLERATED, WITH FAVORABLE SAFETY DATA ACROSS ALL BLINDED SINGLE ASCENDING DOSE (SAD) COHORTS

ABSCI ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FROM THE HEADLINE TRIAL OF ABS-201, A NOVEL ANTIBODY TARGETING THE PROLACTIN RECEPTOR (PRLR)

AUSTIN, TEXAS--(BUSINESS WIRE)---- $HYFT #AI--MINDWALK HOLDINGS CORP. (MINDWALK) (NASDAQ: HYFT), A BIO-NATIVE AI COMPANY, TODAY ANNOUNCED THAT PRESIDENT AND CHIEF EXECUTIVE OFFICER DR. JENNIFER BATH WILL JOIN A VIRTUAL PANEL HOSTED BY JONES, ALONGSIDE ABSCI (NASDAQ: ABSI) AND A LEADING AI COMPUTE PROVIDER, AS PART OF JONES AI DAY. THE PANEL, PARTNERING TO POWER THE NEW ERA OF DRUG DISCOVERY, WILL BE HELD ON MONDAY, JUNE 15, 2026, AT 12:00 P.M. ET. MODERATED BY JONES RESEARCH SENIOR RESEARCH ANALYSTS DR.

MINDWALK (NASDAQ: HYFT) CEO DR. JENNIFER BATH TO JOIN ABSCI (NASDAQ: ABSI) AND A LEADING AI COMPUTE PROVIDER ON JONES AI DAY PANEL ON THE FUTURE OF AI DRUG DISCOVERY

VANCOUVER, WASH. AND NEW YORK, MAY 20, 2026 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

ABSCI TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SUCCESSFULLY DOSED ALL FOUR PLANNED HEALTHY VOLUNTEER SAD COHORTS OF ONGOING ABS-201 HEADLINE TRIAL; WELL-TOLERATED WITH FAVORABLE EMERGING SAFETY DATA PRELIMINARY PHARMACOKINETIC (PK) MODELING FROM HEADLINE TRIAL SUPPORTS ABS-201'S TARGETED DOSING INTERVAL INITIATED DOSING OF FIRST MAD COHORT OF AGA PARTICIPANTS OF ONGOING ABS-201 HEADLINE TRIAL EXPANDING PROLACTIN PROGRAM PORTFOLIO WITH ADDITION OF ABS-202 TO INTERNAL PIPELINE VANCOUVER, WASH. AND NEW YORK, MAY 07, 2026 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE QUARTER ENDED MARCH 31, 2026.

ABSCI REPORTS BUSINESS UPDATES AND FIRST QUARTER 2026 FINANCIAL AND OPERATING RESULTS

VANCOUVER, WASH. AND NEW YORK, MAY 04, 2026 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THAT ON MAY 1, 2026, THE COMPANY GRANTED A NON-STATUTORY STOCK OPTION TO PURCHASE AN AGGREGATE OF 276,200 SHARES OF ITS COMMON STOCK TO ONE NEWLY-HIRED NON-EXECUTIVE EMPLOYEE. THE INDUCEMENT GRANT WAS PREVIOUSLY APPROVED BY THE COMPENSATION COMMITTEE OF ABSCI'S BOARD OF DIRECTORS PURSUANT TO ABSCI'S 2023 INDUCEMENT PLAN (THE INDUCEMENT PLAN), AND IS BEING MADE AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEE'S ACCEPTANCE OF EMPLOYMENT WITH THE COMPANY IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ABSCI ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

VANCOUVER, WASH. AND NEW YORK, APRIL 23, 2026 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL REPORT BUSINESS UPDATES AND FINANCIAL AND OPERATING RESULTS FOR THE FIRST QUARTER 2026 AFTER MARKET CLOSE ON THURSDAY, MAY 7, 2026.

ABSCI TO REPORT BUSINESS UPDATES AND FIRST QUARTER 2026 FINANCIAL AND OPERATING RESULTS ON MAY 7, 2026

VANCOUVER, WASH. AND NEW YORK, APRIL 08, 2026 (GLOBE NEWSWIRE) -- ABSCI CORPORATION (NASDAQ: ABSI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING BREAKTHROUGH THERAPEUTICS DESIGNED WITH GENERATIVE AI, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE UPCOMING 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE.

ABSCI TO PARTICIPATE IN THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

SUCCESSFULLY DOSED FIRST THREE COHORTS IN SAD PORTION OF ONGOING ABS-201 HEADLINE TRIAL; WELL-TOLERATED WITH FAVORABLE EMERGING SAFETY DATA

Absci Corporation

ABSI

Price

Financial Reports

No items found.

Press Releases

Absci Corporation

ABSI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABSI